1,793 results on '"Calmy, Alexandra"'
Search Results
2. Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries
- Author
-
Lepère, Phillipe, Touré, Yélamikan, Bitty-Anderson, Alexandra M, Boni, Simon P, Anago, Gildas, Tchounga, Boris, Touré, Pendadiago, Minga, Albert, Messou, Eugène, Kanga, Guillaume, Koule, Serge, Poda, Armel, Calmy, Alexandra, Ekouevi, Didier K, and Coffie, Patrick A
- Subjects
Information technology ,T58.5-58.64 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundThe use of mobile technology in health care (mobile health [mHealth]) could be an innovative way to improve health care, especially for increasing retention in HIV care and adherence to treatment. However, there is a scarcity of studies on mHealth among people living with HIV (PLHIV) in West and Central Africa. ObjectiveThe aim of this study was to assess the acceptability of an mHealth intervention among PLHIV in three countries of West Africa. MethodsA cross-sectional study among PLHIV was conducted in 2017 in three francophone West African countries: Côte d’Ivoire, Burkina Faso, and Togo. PLHIV followed in the six preselected HIV treatment and care centers, completed a standardized questionnaire on mobile phone possession, acceptability of mobile phone for HIV care and treatment, preference of mobile phone services, and phone sharing. Descriptive statistics and logistic regression were used to describe variables and assess factors associated with mHealth acceptability. ResultsA total of 1131 PLHIV—643 from Côte d’Ivoire, 239 from Togo, and 249 from Burkina Faso—participated in the study. Median age was 44 years, and 76.1% were women (n=861). Almost all participants owned a mobile phone (n=1107, 97.9%), and 12.6% (n=140) shared phones with a third party. Acceptability of mHealth was 98.8%, with the majority indicating their preference for both phone calls and text messages. Factors associated with mHealth acceptability were having a primary school education or no education (adjusted odds ratio=7.15, 95% CI 5.05-10.12; P
- Published
- 2019
- Full Text
- View/download PDF
3. Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
- Author
-
Kusejko, Katharina, Kouyos, Roger D., Bernasconi, Enos, Boggian, Katia, Braun, Dominique L., Calmy, Alexandra, Cavassini, Matthias, van Delden, Christian, Furrer, Hansjakob, Garzoni, Christian, Hirsch, Hans H., Hirzel, Cedric, Manuel, Oriol, Schmid, Patrick, Khanna, Nina, Haidar, Fadi, Bonani, Marco, Golshayan, Dela, Dickenmann, Michael, Sidler, Daniel, Schnyder, Aurelia, Mueller, Nicolas J., Günthard, Huldrych F., and Schreiber, Peter W.
- Published
- 2024
- Full Text
- View/download PDF
4. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocol
- Author
-
Hentzien, Maxime, Bonnet, Fabrice, Bernasconi, Enos, Biver, Emmanuel, Braun, Dominique L., Munting, Aline, Leuzinger, Karoline, Leleux, Olivier, Musardo, Stefano, Prendki, Virginie, Schmid, Patrick, Staehelin, Cornelia, Stoeckle, Marcel, Walti, Carla S., Wittkop, Linda, Appay, Victor, Didierlaurent, Arnaud M., and Calmy, Alexandra
- Published
- 2024
- Full Text
- View/download PDF
5. Transcriptional profile of Mycobacterium tuberculosis infection in people living with HIV
- Author
-
Tepekule, Burcu, Jörimann, Lisa, Schenkel, Corinne D., Opitz, Lennart, Tschumi, Jasmin, Wolfensberger, Rebekka, Neumann, Kathrin, Kusejko, Katharina, Zeeb, Marius, Boeck, Lucas, Kälin, Marisa, Notter, Julia, Furrer, Hansjakob, Hoffmann, Matthias, Hirsch, Hans H., Calmy, Alexandra, Cavassini, Matthias, Labhardt, Niklaus D., Bernasconi, Enos, Oesch, Gabriela, Metzner, Karin J., Braun, Dominique L., Günthard, Huldrych F., Kouyos, Roger D., Duffy, Fergal, and Nemeth, Johannes
- Published
- 2024
- Full Text
- View/download PDF
6. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
- Author
-
Molina, Jean-Michel, Rizzardini, Giuliano, Orrell, Catherine, Afani, Alejandro, Calmy, Alexandra, Oka, Shinichi, Hinestrosa, Federico, Kumar, Princy, Tebas, Pablo, Walmsley, Sharon, Grandhi, Anjana, Klopfer, Stephanie, Gendrano, Isaias, Eves, Karen, Correll, Todd A, Fox, Michelle C, and Kim, Jason
- Published
- 2024
- Full Text
- View/download PDF
7. Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study
- Author
-
Thoueille, Paul, Delfraysse, Margot, Andre, Pascal, Buclin, Thierry, Decosterd, Laurent A., Fedeli, Chiara, Ustero, Pilar, Calmy, Alexandra, and Guidi, Monia
- Published
- 2023
- Full Text
- View/download PDF
8. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
- Author
-
Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, Inciarte Portillo, Alexy, Cahn, Pedro, Lombaard, Johannes, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, and Lahoulou, Rima
- Published
- 2024
- Full Text
- View/download PDF
9. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
- Author
-
Abela, I, Aebi-Popp, K, Anagnostopoulos, A, Battegay, M, Bernasconi, E, Braun, DL, Bucher, HC, Calmy, A, Cavassini, M, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Günthard, HF, Hachfeld, A, Haerry, D, Hasse, B, Hirsch, HH, Hoffmann, M, Hösli, I, Huber, M, Jackson-Perry, D, Kahlert, CR, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, RD, Kovari, H, Kusejko, K, Labhardt, N, Leuzinger, K, Martinez de Tejada, B, Marzolini, C, Metzner, KJ, Müller, N, Nemeth, J, Nicca, D, Notter, J, Paioni, P, Pantaleo, G, Perreau, M, Rauch, A, Salazar-Vizcaya, L, Schmid, P, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Wandeler, G, Weisser, M, Yerly, S, Thoueille, Paul, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva, Munting, Aline, Cavassini, Matthias, Braun, Dominique, Günthard, Huldrych F., Kusejko, Katharina, Surial, Bernard, Furrer, Hansjakob, Rauch, Andri, Rougemont, Mathieu, Ustero, Pilar, Calmy, Alexandra, Stöckle, Marcel, Marzolini, Catia, Di Benedetto, Caroline, Bernasconi, Enos, Schmid, Patrick, Piso, Rein Jan, Andre, Pascal, Girardin, François R., Guidi, Monia, Buclin, Thierry, and Decosterd, Laurent A.
- Published
- 2024
- Full Text
- View/download PDF
10. Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional Study
- Author
-
Mauri, Fabio, Cottler-Casanova, Sara, Cavassini, Matthias, Stoeckle, Marcel, Wandeler, Gilles, Schmid, Patrick, Braun, Dominique L, Scherrer, Alexandra, Bernasconi, Enos, Calmy, Alexandra, and Abdulcadir, Jasmine
- Published
- 2023
- Full Text
- View/download PDF
11. Mpox in people with advanced HIV infection: a global case series
- Author
-
Leiro, Viviana, Marchetta, Lucila, Fernandez Pardal, Patricia, Figueroa, María Inés, Cahn, Pedro, Grabmeier-Pfistershammer, Katharina, Libois, Agnes, Liesenborghs, Laurens, Grinsztejn, Beatriz, Schechter, Mauro, dos Santos de Lemos, Alberto, Furtado Costa, Alvaro, Queiroz Rocha, Simone, Valdez Madruga, José, S. Tan, Darrell H., Mishra, Sharmistha, Shah, Shreya, Jorquera, Camila, Castillo, Alberto, Carrión, Mauricio, Cevallos, Nelson, Palich, Romain, Pourcher, Valerie, Rubenstein, Emma, Migaud, Pascal, Boesecke, Christoph, Hoffmann, Christian, Protopapas, Konstantinos, Nozza, Silvia, Cattelan, Anna Maria, Mussini, Cristina, d'Arminio Monforte, Antonella, Cruz Flores, Raúl Adrian, Pérez Barragán, Edgar, Rodríguez Guzmán, Alma Leticia, Ogoina, Dimie, Chika-Igwenyi, Nneka Marian, Chizaram, Onyeaghala, Valverde López, Jenny, García Tello, Angelica, Ubals, Maria, Vall, Martí, Mendoza, Adrià, Suñer, Clara, Clotet, Bonaventura, Bechini, Jordi, Lepe, Jose A, Navarro-Amuedo, M. Dolores, Bernadino, Jose Ignacio, Català, Alba, Tarín Vicente, Eloy José, González Rodríguez, Borja, Rodriguez-Mercader, Sergi, Sánchez-Martinez, Francisca, Cañas-Ruano, Esperanza, Parra-Navarro, Laura, Filén, Finn, Tallón de Lara, Carmen, Braun, Dominique, Piezzi, Vanja, Burkhard, Michael, Kovari, Helen, Mönch, Anja, Dunning, Jake, Simoes, Pedro, Nori, Achyuta, Keegan, Sarah, Thornhill, John P, Apea, Vanessa, Noori, Teymur, Jones, Joyce L., Judson, Seth, Gilliams, Elizabeth A., Hamill, Matthew M., Keruly, Jeanne, Henao Martínez, Andrés F., Lin, Aung, So, Jessica, Davar, Kusha, Villareal, Diana, Tapia Paredes, Miguel, Mitjà, Oriol, Alemany, Andrea, Marks, Michael, Lezama Mora, Jezer I, Rodríguez-Aldama, Juan Carlos, Torres Silva, Mayara Secco, Corral Herrera, Ever Arturo, Crabtree-Ramirez, Brenda, Blanco, José Luis, Girometti, Nicolo, Mazzotta, Valentina, Hazra, Aniruddha, Silva, Macarena, Montenegro-Idrogo, Juan José, Gebo, Kelly, Ghosn, Jade, Peña Vázquez, María Fernanda, Matos Prado, Eduardo, Unigwe, Uche, Villar-García, Judit, Wald-Dickler, Noah, Zucker, Jason, Paredes, Roger, Calmy, Alexandra, Waters, Laura, Galvan-Casas, Cristina, Walmsley, Sharon, and Orkin, Chloe M
- Published
- 2023
- Full Text
- View/download PDF
12. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study
- Author
-
Salgado, Maria, primary, Gálvez, Cristina, additional, Nijhuis, Monique, additional, Kwon, Mi, additional, Cardozo-Ojeda, E Fabian, additional, Badiola, Jon, additional, Gorman, Matthew J, additional, Huyveneers, Laura E P, additional, Urrea, Victor, additional, Bandera, Alessandra, additional, Jensen, Björn-Erik Ole, additional, Vandekerckhove, Linos, additional, Jurado, Manuel, additional, Raj, Kavita, additional, Schulze zur Wiesch, Julian, additional, Bailén, Rebeca, additional, Eberhard, Johanna M, additional, Nabergoj, Mitja, additional, Hütter, Gero, additional, Saldaña-Moreno, Raquel, additional, Oldford, Sharon, additional, Barrett, Lisa, additional, Ramirez, Maria Luisa Montes, additional, Garba, Salisu, additional, Gupta, Ravi Kumar, additional, Revollo, Boris, additional, Ferra-Coll, Christelle, additional, Kuball, Jurgen, additional, Alter, Galit, additional, Sáez-Cirión, Asier, additional, Diez-Martin, Jose Luis, additional, Duke, Elizabeth R, additional, Schiffer, Joshua T, additional, Wensing, Annemarie, additional, Martinez-Picado, Javier, additional, Muscatello, Antonio, additional, Calmy, Alexandra, additional, Chapel, Anais, additional, Mamez, Anne-Claire, additional, Passaes, Caroline, additional, Brisseau, Clarissa, additional, Olivarria, Eduardo, additional, Knops, Elena, additional, Heger, Eva, additional, Bikhezar, Fatima, additional, Perdomo-Celis, Federico, additional, Kobbe, Guido, additional, Gabriel, Ian H, additional, Lunzen, Jan V, additional, Dalmau, Judith, additional, Martín-Carbonero, Luz, additional, Puertas, Mari Carmen, additional, Garcia-Guerrero, Mari Carmen, additional, de Scheerder, Marie-Angélique, additional, Angin, Mathieu, additional, Lübke, Nadine, additional, Balsalobre, Pascual, additional, de Paz, Raquel, additional, Kaiser, Rolf, additional, Kerre, Tessa, additional, Harrer, Thomas, additional, Luedde, Tom, additional, and Rocha, Vanderson, additional
- Published
- 2024
- Full Text
- View/download PDF
13. The international Unity study for antivirals against mpox is a blueprint for future epidemics
- Author
-
Telford, Erica, Grinsztejn, Beatriz, Olsen, Inge Christoffer, Pulik, Nicolas, Mentré, France, Haviari, Skerdi, Hentzien, Maxime, Ségéral, Olivier, Ekkelenkamp, Miquel B., Ogoina, Dimie, Strub-Wourgaft, Nathalie, Diallo, Alpha, Yazdanpanah, Yazdan, and Calmy, Alexandra
- Published
- 2023
- Full Text
- View/download PDF
14. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
- Author
-
Phillips, Andrew N, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel, Wensing, Annemarie, Lundgren, Jens D, De Luca, Andrea, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Bansi-Matharu, Loveleen, Nakagawa, Fumiyo, Kalua, Thokozani, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Clayden, Polly, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Bertagnolio, Silvia, and Calmy, Alexandra
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Prevention ,HIV/AIDS ,Pediatric ,Aetiology ,Evaluation of treatments and therapeutic interventions ,2.2 Factors relating to the physical environment ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Africa South of the Sahara ,Antiretroviral Therapy ,Highly Active ,Developmental Disabilities ,Drug Resistance ,Viral ,Female ,HIV Infections ,HIV Integrase Inhibitors ,Heterocyclic Compounds ,3-Ring ,Humans ,Male ,Middle Aged ,Oxazines ,Piperazines ,Pregnancy ,Pyridones ,Risk Assessment ,Sustained Virologic Response ,Treatment Outcome ,Viral Load ,Young Adult ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundThe integrase inhibitor dolutegravir could have a major role in future antiretroviral therapy (ART) regimens in sub-Saharan Africa because of its high potency and barrier to resistance, good tolerability, and low cost, but there is uncertainty over appropriate policies for use relating to the potential for drug resistance spread and a possible increased risk of neural tube defects in infants if used in women at the time of conception. We used an existing individual-based model of HIV transmission, progression, and the effect of ART with the aim of informing policy makers on approaches to the use of dolutegravir that are likely to lead to the highest population health gains.MethodsWe used an existing individual-based model of HIV transmission and progression in adults, which takes into account the effects of drug resistance and differential drug potency in determining viral suppression and clinical outcomes to compare predicted outcomes of alternative ART regimen policies. We calculated disability adjusted life-years (DALYs) for each policy, assuming that a woman having a child with a neural tube defect incurs an extra DALY per year for the remainder of the time horizon and accounting for mother-to-child transmission. We used a 20 year time horizon, a 3% discount rate, and a cost-effectiveness threshold of US$500 per DALY averted.FindingsThe greatest number of DALYs is predicted to be averted with use of a policy in which tenofovir, lamivudine, and dolutegravir is used in all people on ART, including switching to tenofovir, lamivudine, and dolutegravir in those currently on ART, regardless of current viral load suppression and intention to have (more) children. This result was consistent in several sensitivity analyses. We predict that this policy would be cost-saving.InterpretationUsing a standard DALY framework to compare health outcomes from a public health perspective, the benefits of transition to tenofovir, lamivudine, and dolutegravir for all substantially outweighed the risks.FundingBill & Melinda Gates Foundation.
- Published
- 2019
15. Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial
- Author
-
Maitre, Thomas, Bonnet, Maryline, Calmy, Alexandra, Raberahona, Mihaja, Rakotoarivelo, Rivonirina Andry, Rakotosamimanana, Niaina, Ambrosioni, Juan, Miró, José M., Debeaudrap, Pierre, Muzoora, Conrad, Davis, Angharad, Meintjes, Graeme, Wasserman, Sean, Wilkinson, Robert, Eholié, Serge, Nogbou, Frédéric Ello, Calvo-Cortes, Maria-Camilla, Chazallon, Corine, Machault, Vanessa, Anglaret, Xavier, and Bonnet, Fabrice
- Published
- 2022
- Full Text
- View/download PDF
16. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
- Author
-
Pan, Hongchao, Peto, Richard, Henao Restrepo, Ana Maria, Preziosi, Marie-Pierre, Sathiyamoorthy, Vasee, Karim, Quarraisha Abdool, Alejandria, Marissa, Hernàndez García, César, Kieny, Marie-Paule, Malekzadeh, Reza, Murthy, Srinivas, Reddy, K. Srinath, Periago, Mirta Roses, Hanna, Pierre Abi, Abutidze, Akaki, Ader, Florence, Al-Bader, Abdullah, Alhasawi, Almonther, Allum, Emma, Al Mawali, Adhra, Alotaibi, Athari, Alvarez- Moreno, Carlos, Appadoo, Sheila, Arts, Derk, Asiri, Abdullah, Aukrust, Pål, Barratt-Due, Andreas, Genetu Bayih, Abebe, Beaumont, Helena, Bellani, Samir, Benassi, Virginia, Bhargava, Balram, Branca, Mattia, Cappel-Porter, Heike, Cerrato, Nery, Cheick Haidara, Fadima, Chow, Ting Soo, Como, Nadia, Eustace, Joe, Gabunia, Tamar, García, Patricia, Godbole, Sheela, Gotuzzo, Eduardo, Griskevicius, Laimonas, Hamra, Rasha, Hassan, Mariam, Hassany, Mohamed, Hutton, David, Irmansyah, Irmansyah, Jancoriene, Ligita, Khamis, Faryal, Kirwan, Jana, Kumar, Suresh, Lennon, Peter, Lopardo, Gustavo, Lydon, Patrick, Magrini, Nicola, Manevska, Suzana, Manuel, Oriol, McGinty, Sybil, Medina, Marco, Mesa Rubio, Maria Lucia, Miranda Montoya, Maria Consuelo, Nel, Jeremy, Nunes, Estevao, Perola, Markus, Portoles, Antonio, Rasmin, Menaldi, Raza, Aun, Rees, Helen, Reges, Paula, Rogers, Chris, Salami, Kolawole, Salvadori, Marina, Sauermann, Mamatha, Sinani, Narvina, Sow, Samba, Sterne, Jonathan AC, Stevanovikj, Milena, Tacconelli, Evelina, Tavares Maltez, Fernando Manuel, Teferi, Mekonnen, Tikkinen, Kari, Trelle, Sven, Tsertsvadze, Tengiz, Zaid, Hala, Røttingen, John-Arne, Swaminathan, Soumya, Ryan, Michael, Gjermeni, Nevila, Meta, Esmeralda, Aguila, Damian, Alonso, Ignacio, Altamirano, Marcos, Alvarez, María, Alzola, Rodrigo, Arce, Veronica, Arribillaga, Patricia, Avila, Rafael, Balbuena, Juan, Barcelona, Laura, Barletta, José, Benedetti, María, Berdiñas, Verónica, Burgui, Julieta, Caimi, Sabrina, Carrillo, Juan, Carrizo, Juan, Castelli, Juan, Cazaux, Alexis, Cervellino, Flavia, Chalco, Angelo, Chediack, Viviana, Cunto, Eleonora, D'Amico, Nicolàs, de Vedia, Lautaro, Delgado, Carolina, Di Pilla, Debora, Díaz, Miguel, Díaz Aguiar, Pablo, Domínguez, Cecilia, Ellero, Leonor, Farina, Javier, Fernàndez, José, Ferreyra, Roxana, Filippi, María, Fogar, Carolina, Frare, Pablo, Giudiche, Celeste, Golikow, Mariana, Gomez, Maria Georgina, Hermida, Laura, Hurtado, Mariano, Jacobo, Mariela, Jaume, Martin, Laplume, Diego, Lescano, María, Lista, Nicolàs, Loiacono, Flavia, López, Ana Belen, Losso, Marcelo, Luna, Cecilia, Lupo, Sergio, Marianelli, Leonardo, Martin, Anabella, Masciottra, Florencia, Mykietiuk, Analía, Orellano, Lorena, Pachioli, Valeria, Padilla, María José, Pallavicini, Cecilia, Patroso, Jazmin, Perez Blanco, Luz, Presas, Jose Louis, Provenzano, Matias, Lavera, Lorena, Reichert, Viviana, Riveros, Florencia, Rodríguez, Alejandra, Rolon, María José, Salvay, Carolina, Simonetta, María, Sisto, Alicia, Themines, Sandra, Tito, Fernando, Toibaro, Javier, Torales, Graciela, Verón, Luciano, Vizzotti, Carla, Egle, Alexander, Greil, Richard, Joannidis, Michael, Altdorfer, Antoine, Belkhir, Leila, Fraipont, Vincent, Hites, Maya, Arruda, Erico, Breda, Giovanni, Colussi, Arthur, Corradi, Miran, Croda, Julio, Duani, Helena, João, Esaú, Machado, Elizabeth, Mello, Fernanda, Miranda Filho, Demócrito, Monteiro, Poliana, Nunes, Ceuci, Pereira Junior, Luiz Carlos, Pinto, Gustavo, Raboni, Sonia, Ramos, Marcelo, Ruffing, Leonardo, Santos, Valdilea, Souza, Tamara, Medeiros, Melissa, Schwarzbold, Alexandre, Ali, Karim, Azher, Tanweer, Bellemare, David, Binnie, Alexandra, Borgia, Sergio, Cavayas, Yiorgos Alexandros, Chagnon, Nicholas, Cheng, Matthew, Cloutier, Eve, Conly, John, Costiniuk, Cecilia, Daneman, Nick, Douglas, James, Downey, Catarina, Duan, Erick, Durand, Medeline, English, Shane, Farjou, George, Fera, Evadiki, Fontela, Patricia, Fowler, Rob, Fralick, Mike, Gamble, David Gregory, Geagea, Anna, Grant, Jennifer, Harrison, Luke, Havey, Thomas, Hoang, Holly, Kelly, Lauren, Keynan, Yoav, Khwaja, Kosar, Klein, Marina, Kolan, Christophe, Kronfli, Nadine, Lamontagne, Francois, Lee, Nelson, Lee, Todd, Lim, Rachel, Lostun, Alexandra, MacIntyre, Erika, Malhamé, Isabelle, Martin-Carrier, Francois, McGuinty, Marlee, Munan, Matthew, O'Neil, Conar, Ovakim, Daniel, Papenburg, Jesse, Parhar, Ken, Parvathy, SeemaNair, Perez-Patrigeon, Santiago, Rishu, Asgar, Rushton, Moira, Scherr, Kim, Schwartz, Kevin, Semret, Makeda, Silverman, Micahel, Singh, Ameeta, Sligl, Wendy, Smith, Stephanie, Somayaji, Ranjani, Tan, Darrell, Tran, Tuong-Vi, Tremblay, Alain, Tsang, Jennifer, Turgeon, Alexis, Vakil, Erik, Weatherald, Jason, Yansouni, Cedric, Zarychanski, Ryan, Aristizabal, Claudia, Bravo, Juan, Caicedo, Monica, Chacón, Julio, Garzón, Diego, Guevara, Fredy, Lozano-Gonzàlez, Silvia, Macareno, Hugo, Montañez-Ayala, Anita, Oñate, Jose, Rojas-Gambasica, Jose, Rosso, Fernando, Saavedra, Carlos, Valderrama, Sandra, Vàquiro-Herrera, Eliana, Varón-Vega, Fabio, Zuluaga, Ivan, Abdel Baki, Amin, Abdelbary, Akram, Abdel-Razek, Wael, Amin, Wagdi, Asem, Noha, Elassal, Gehan, Elshesheny, Marwa, Fathy, Mohamed, Fathy, Naglaa, Fayed, Notaila, Hammam, Ahmed, Hassany, Sahar, Ibrahim, Hamdy, Kamal, Ehab, Masoud, Hossam, Mohamed, Maryam, Mohamed Gouda, Abdullah, Moustafa, Ehab, Okasha, Shaimaa, Rafik, Ahmed, Said, Ahmed, Sedky, Asmaa, Solyman Kabil, Mohamed, Tarek, Sara, Tharwat, Ahmed, Zaky, Samy, Abegaz, Emawayish Tesema, Bekele, Zelalem Mekonnen, Asfaw, Filmona Mekuria, Tegegne, Netsanet Aragaw, Teklemariam, Miheret Fikre, Nigusse, Frehiwot Tamiru, Achalu, Daniel Legesse, Weldegergs, Shewit Tesfagabr, Huluka, Dawit Kebede, Tereda, Addisu Birhanu, Ala-Kokko, Tero, Delany, Jutta, Ekroos, Heikki, Hankkio, Riina, Haukipää, Mia, Hetemäki, Iivo, Holma, Pia, Holmberg, Ville, Horstia, Saana, Jalkanen, Ville, Jämsänen, Toni, Järventie, Juuso, Järvinen, Petrus, Kalliala, Ilkka, Kauma, Heikki, Kilpeläinen, Tuomas, Kreivi, Hanna-Riikka, Kuitunen, Ilari, Lamminmäki, Satu, Mäkinen, Laura, Mäntylä, Jarkko, Mattila, Tiina, Myllärniemi, Marjukka, Niskanen, Joni, Nykänen, Taina, Nyqvist, Miro, Paajanen, Juuso, Partanen, Terhi, Patovirta, Riitta-Liisa, Paukkeri, Erja-Leena, Puusti, Emmi, Renner, Andreas, Reponen, Emma, Risku, Sari, Rosberg, Tuomas, Rutanen, Jarno, Säilä, Petrus, Salonen, Päivi, Sinisalo, Marjatta, Sivenius, Katariina, Tuominen, Susanna, Aboab, Jerone, Alfaiate, Toni, Andrejak, Claire, Andreu, Pascal, Belhadi, Drifa, Benezit, Francois, Botelho-Nevers, Elisabeth, Bouadma, Lila, Bougon, David, Bouiller, Kevin, Bounes, Fanny, Boyer, Alexandre, Bruel, Cédric, Buffet, Alexandre, Burdet, Charles, Cazanave, Charles, Chabertier, Cyrille, Clere-Jehl, Rapahel, Costagliola, Dominique, Courjon, Johan-Victor, Crockett, Flora, Danion, Francois, Dechanet, Aline, Dellamonica, Jean, Delmas, Christelle, Diallo, Alpha, Djossou, Felix, Dubost, Clement, Dupont, Axelle, Epaulard, Olivier, Faure, Emmmanuel, Faure, Karine, Fayol, Antoine, Figueiredo, Samy, Fougerou, Claire, Gaborit, Benjamin, Gaci, Rostane, Gagneux-Brunon, Amandine, Gallien, Sebastien, Garot, D, Goehringer, Francois, Gruson, Didier, Hinschberger, Olivier, Hulot, Jean-Sebastien, Jaureguiberry, Stephane, Jean-Michel, Vanessa, Kerneis, Solen, Kimmoun, Antoine, Klouche, Kada, Lachatre, Marie, Lacombe, Karine, Laine, Fabrice, Lanoix, Jean Philippe, Laribi, Samira, Launay, Odile, Laviolle, Bruno, Le Moing, Vincent, Le Pavec, Jerome, Lebeaux, David, Leroy, Sylvie, Lescure, Xavier, Livrozet, Marine, Makinson, Alain, Malvy, Denis, Marquette, Charles-Hugo, Martin-Blondel, Guillaume, Mayaux, Julien, Mekontso Dessap, Armand, Mentre, France, Mercier, Noemie, Meziani, Ferhat, Molina, Jean Michel, Mootien, Yoganaden, Mourvillier, Bruno, Navellou, Jean Christoph, Noret, M, Peiffer- Smadja, Nathan, Peytavin, Gilles, Pialoux, Gilles, Pilmis, Benoît, Piroth, Lionel, Poindron, Vincent, Poissy, Julien, Pourcher, Valerie, Quenot, Jean Pierre, Raffi, Francois, Reignier, Jean, Richard, Jean Christoph, Robert, Céline, Saillard, Juliette, Sayre, Naomi, Senneville, Eric, Stefan, Francois, Tellier, Marie Capucine, Terzi, Nicolas, Textoris, Julien, Thiery, Guillame, Timsit, Jean Francois, Tolsma, Violaine, Tubiana, Sarah, Wallet, Florent, Yazdanpanah, Yazdan, Zerbib, Yoann, Aguilar, Carlos, Erazo, Laura, Fiallos, Angel, Figueroa, Rosbinda, Flores, Juan Jose, Melendez, Lesddyy, Moncada, Wendy, Abraham, Ooriapadickal Cherian, Acharya, Chetankumar, Aedula, Vinaya Sekhar, Aggarwal, Richa, Agrawal, Nishant, Agrawal, Umang, Agrawal, Abhishekh, Ahmad, Mohammad, Atal, Shubham, Babu, Avinash, Baidya, Dalim Kumar, Balachandran, Amith, Bangar, Rakhee, Bhadade, Rakesh, Bhandari, Sudhir, Bhapal, Meghavi, Bhardwaj, Pankaj, Bhati, Gaurav, Bhatia, Pradeep, Bhatt, Krishnakant, Bingi, Thrilok Chander, Borse, Rohidas, Buch, Vyom, Chand, Dipti, Chandwani, Ashish, Charan, Jaykaran, Chaudhari, Mayur, Chaudhari, Kirti, Chaudhary, Vipul, Chauhan, Nishant, Chikara, Gaurav, Daswani, Bharti, de Souza, Rosemarie, Desai, Chetna, Divakar, Balusamy, Divhare, Sujeet, Dorairajan, Suresh Kumar, Dutt, Naveen, Ethirajan, Therani Rajan, Gamit, Amit, Gamit, Sweta, Garg, Mahendra, Goenka, Ajay, Goenka, Aniket, Guleria, Randeep, Gupta, Paras, Gupta, Nivedita, Gupta, Madhur, Harde, Minal, Ingle, Vaibhav, Iyer, Shivkumar, Jamalapuram, Vaishnavi, Jayanthi, Rangarajan, Joshi, Rajnish, Kadam, Abhijeet, Kalakuntla, Hemanth, Kalikar, Mrunalini, Kalme, Sayali, Kamble, Suchit, Kant, Ravi, Kantharia, Bansari, Kashikar, Arundhati, Kavishvar, Abhay, Kayina, Choro Athipro, Kerkar, Pranali, Khadanga, Sagar, Khandare, Sagar, Kokate, Pranjali, Komathi, Jayavelu, Krishnan, Vijay, Krishnan, Jayasree, Krishnan, Sumitra, Kulur Mukhyaprana, Sudha, Kumarasamy, N, Mahavar, Sunil, Maitra, Souvik, Majumdar, Falguni, Malhotra, Supriya, Mamulwar, Megha, Malini, Padma, Marwah, Vikas, Maurya, Akhilesh, Mehta, Kedar, Mesipogu, Rajarao, Misra, Shobha, Mitra, Sajal, Mittal, Ankit, Mohan, Bharathi, Momin, Mohmmedirfan, Nag, Vijaya, Nagarajan, Ramakrishnan, Nagmani, Kammili, Narlawar, Uday, Natarajan, Gopalakrishnan, Nischal, Neeraj, Ogale, Dhananjay, Palat, Paltial, Panda, Prasan, Panda, Samiran, Pandya, Amee, Parate, Rohit, Paritekar, Arunita, Patel, Parvati, Patel, Chetna, Patel, Sunaina, Patel, Vitan, Patel, Deep, Patel, Harshad, Patil, Girish, Peter, Deepu, Prasad, Durga, Purohit, Vimlesh, Rabindrarajan, Ebenezer, Ranganathan, Lakshmiarasimhan, Rao, Tushara, Rao, Chakradhara, Rathod, Chirag, Raval, Devang, Ray, Avik, Reddy, Kamini, Rege, Sujata, Revathi, Ayyasamy, Roy, Dhara, Saigal, Saurabh, Sane, Suvarna, Sangale, Shashi, Seetharaman, Krishnamoorthy, Selvamuthu, Poongulali, Seshaiah, Kurada Venkata, Shadrach, Benhur, Shah, Jignesh, Shah, Sonal, Sharma, Swati, Sharma, Raman, Sharma, Shrikant, Singh, Krishna, Singh, Anil, Singh, Arjeet, Singhai, Abhishek, Soneja, Manish, Soni, Kapil Dev, Subhan, Thasneem banu, Subramaniam, Sudharshini, Sudarsanam, Thambu David, Sudarsi, Ravindra Kumar, Suleman, Dawood, Suthar, Nilay, Talati, Shriraj, Tambe, Murlidhar, Tejomurtula, Tilak, Tirupakuzhi Vijayaraghavan, Bharatkumar, Trikha, Anjan, Trivedi, Aarti, Udwadia, Zarir, Upadhyay, Kamlesh, Vasava, Ashwin, Vasudevan, Damodaran, Velayudham, Rajendran, Venkatasubramanian, Ramasubramanian, Verma, Mamta, Waghmare, Rakesh, Waikar, Anushka, Wig, Naveet, Afrilia, Annisa Rizky, Amin, Muhammad, Arlinda, Dona, Avrina, Rossa, Bang, Lois, Djaharuddin, Irawaty, Djojo, Aryan, Driyah, Sri Laning, Erastuti, Mila, Fajarwati, Tetra, Harsini, Harsini, Hartantri, Yovita, Herman, Deddy, Isbaniah, Fathiyah, Karyana, Muhammad, Kusuma, Indra, Mahmudji, Harli Amir, Medison, Irvan, Nugroho, Agung, Nurhayati, Nurhayati, Opitasari, Cicih, Pitoyo, Ceva Wicaksono, Pradana, Antonius Arditya, Raharjo, Sofyan Budi, Rahmaini, Ade, Risniati, Yenni, Riyanto, Bambang Sigit, Sajinadiyasa, I Gede Ketut, Sari, Flora Eka, Sitompul, Pompini Agustina, Soedarsono, Soedarsono, Somia, I Ketut Agus, Sugiri, Yani Jane, Sugiyono, Retna Indah, Susanto, Nugroho Harry, Syarif, Armaji Kamaludi, Yulianto, Aris, Afsharian, Mandana, Akhavi Mirab, Atefehsadat, Amini, Fatemeh, Amini, Mahnaz, Ansarin, Khalil, Baba Mahmoodi, Farhang, Baghaei, Parvaneh, Barazandeh, Fateme, Bayani, Masomeh, Dastan, Farzaneh, Ebrahimpour, Soheil, Eghtesad, Sareh, Fallahi, Mohammad Javad, Fallahpoor Golmaee, Fatemeh, Foroghi Ghomi, Seyed Yaser, Ghadir, Mohammad Reza, Gheitani, Mina, Ghiasvand, Fereshteh, Hafizi Lotfabadi, Saied, Hakamifard, Atousa, Hashemi Madani, Shima Sadat, Hormati, Ahmad, Hosseini, Hamed, Janbakhsh, Alireza, Javanian, Mostafa, Joukar, Farahnaz, Kamali, Alireza, Karampour, Amin, Khajavirad, Nasim, Khodabakhshi, Behnaz, Khodadadi, Javad, Khodashahi, Rozita, Kiani Majd, Somaieh, Mahfoozi, Lida, Mahmoodiyeh, Behnam, Mansour-Ghanaei, Fariborz, Mansouri, Feizollah, Mesgarpour, Bita, Mesri, Mehdi, Mikaeili, Haleh, Miladi, Ronak, Moghadami, Mohsen, Mohamadi, Payam, Mohraz, Minoo, Mohseni Afshar, Zeinab, Moogahi, Sasan, Mousavi Anari, Seyed Alireza, Mozaffar, Seyyed Hassan, Mozdourian, Mahnaz, Najafipour, Reza, Najari, Hamidreza, Nazemiyeh, Masoud, Norouzi, Alireza, Pourkazemi, Aydin, Poustchi, Hossein, Saberhosseini, Seyedeh Naeimeh, Saberi, Marzieh, Saber-Moghaddam, Niloufar, Sadeghi, Anahita, Sadeghi Haddad Zavareh, Mahmoud, Sahraian, Mohammad Ali, Salahi, Mehrdad, Salehi, Mohammad Reza, Sarmadian, Hossein, Sayad, Babak, Shirani, Kiana, Shirvani, Maria, Shojaei, Daryanaz, Shokri, Mehran, Siami, Zeinab, Sima, Ali Reza, Soleimani, Alireza, Soltanmohammad, Saedeh, Tabarsi, Payam, Taghizadieh, Ali, Tavassoli, Samaneh, Varnasseri, Mehran, Vaziri, Siavash, Yadyad, Mohammad Jaafar, Yaghoubi, Shoeleh, Yazdanpanah, Yalda, Yousefi, Farid, Zamanian, Mohammad Hossein, Zand, Farid, Zare Hoseinzade, Elham, Bergin, Colm, Cotter, Aoife, de Barra, Eoghan, Jackson, Arthur, Laffey, John, McCarthy, Cormac, Muldoon, Eavan, Sadlier, Corinna, Maguire, Teresa, Angheben, Andrea, Bai, Francesca, Bandera, Alessandra, Barchiesi, Francesco, Bassetti, Matteo, Bisi, Luca, Bonfanti, Paolo, Calò, Federica, Campoli, Caterina, Canovari, Benedetta, Capetti, Amedeo, Castelli, Francesco, Cauda, Roberto, Cingolani, Antonella, Cocco, Nicolò, Coppola, Nicola, Corcione, Silvia, Cremonini, Eleonora, d'Arminio Monforte, Antonella, de Gaetano Donati, Katleen, De Nardo, Pasquale, De Rosa, Francesco Giuseppe, Degioanni, Maria, Della Siega, Paola, Di Bella, Stefano, Drera, Bruno, Focà, Emanuele, Fornabaio, Chiara, Galli, Massimo, Giacomazzi, Donatella, Gori, Andrea, Gustinetti, Giulia, Iannuzzi, Francesca, Kertusha, Blerta, Lamonica, Silvia, Lichtner, Miriam, Lupia, Tommaso, Luzzati, Roberto, Macera, Margherita, Menatti, Elisabetta, Merelli, Maria, Merlini, Esther, Monari, Caterina, Pan, Angelo, Pecori, Davide, Pezzani, Diletta, Riccardi, Niccolò, Rodari, Paola, Roldan, Eugenia, Rovere, Pierangelo, Rusconi, Stefano, Scabini, Silvia, Tascini, Carlo, Viale, Pierluigi, Vincenzi, Marcello, Zuccalà, Paola, Zucchi, Patrizia, Al-Roomi, Moudhi, Al-Sabah, Salman, Schrapp, Kelly, Hassoun, Mahmoud, Matar, Madonna, Dbouni, Oussaima, Yared, Nadine, Saliba, Michele, Farra, Anna, Riachi, Moussa, Zablockiene, Birute, Reuter, Jean, Staub, Therese, Ab Wahab, Suhaila, Chew, Chun Keat, Chua, Hock Hin, Goh, Pik Pin, Lee, Heng Gee, Leong, Chee Loon, Low, Lee Lee, Mak, Wen Yao, Mohamed Gani, Yasmin, Muhamad, Dzawani, Zaidan, Nor Zaila, Ducker, Camilla, Demiri, Ilir, Aballi, Saad, Berg, Åse, Blomberg, Bjørn, Dalgard, Olav, Dyrhol-Riise, Anne Ma, Eiken, Ragnhild, Ernst, Gernot, Hannula, Ranula, Haugli, Metter, Heggelund, Lars, Hoel, Hedda, Hoff, Dag Arne Lihaug, Holten, Aleksander Rygh, Johannessen, Asgeir, Kåsine, Trine, Kildal, Anders Benjamin, Kittang, Bård Reikvam, Nezvalova-Henriksen, Katerina, Olsen, Inge Christoffer, Olsen, Roy Bjørkolt, Skei, Nina Vibeche, Skudal, Hilde, Tholin, Birgitte, Thoresen, Lars, Trøseid, Marius, Tveita, Anders, Vinge, Leif, Ystrøm, Carl Magnus, Al Jahdhami, Issa, AlNaamani, Khalid, Al Balushi, Zakariya, Pandak, Nenad, Abbas, Salma, Akhtar, Nasim, Azam, Sumeyya, Begum, Dilshad, Hassan, Sadia, Herekar, Fivzia, Khan, Shahzaib, Khan, Ejaz Ahmed, Mahmood, Syed Faisal, Nasir, Nosheen, Rahim, Anum, Sarfaraz, Samreen, Shaikh, Qurat-ul-Ain, Sultan, Faisal, Walayat, Usman, Agurto-Lescano, Erika Cecilia, Alcantara-Díaz, Andrés Martín, Alva-Correa, Ana María, Alvarado-Moreno, José Gustavo, Ángeles-Padilla, Bethsabé, Arbañil-Huamàn, Hugo César, Ávila-Reyes, Pool Christopher, Azañero-Haro, Johan Alexander, Barreto-Rocchetti, Luis Guillermo, Benitez-Peche, Jorge Marko A., Bernal-Màlaga, Karla Hortencia, Cabrera-Portillo, Liliana Norma, Carazas-Chavarry, Reynaldo Javier, Càrcamo, Paloma Mariana, Casimiro-Porras, Indira Catalina, Castillo-Espinoza, Jhuliana, Chacaltana-Huarcaya, Jesús Norberto, Cornejo-Valdivia, Carla Raquel, Cruz-Chereque, Augusto, Del-Aguila-Torres, Keith Cayetano Marcelino, Díaz-Chipana, Erika, Flores-Valdez, Neil, Franco-Vàsquez, Rosanna Andrea, Gallegos-López, Roxana Consuelo, Gastiaburú-Rodriguez, Dauma Yesenia, Gianella-Malca, Gonzalo Ernesto, Gomero-Lopez, Andrés Alonso, Hercilla-Vàsquez, Luis Enrique, Hueda-Zavaleta, Miguel Ángel, Ibarcena-Llerena, Claudia Vanessa, Iberico-Barrera, Carlos Alberto, Inquilla-Castillo, Miguel Angel, Juàrez-Eyzaguirre, Jesus Alberto, Laca-Barrera, Manuel, León-Jiménez, Franco, Luna-Wilson, Carla Vanessa, Màlaga, German, Marin, Ricardo, Mejía-Cordero, Fernando, Mendoza-Laredo, Juan Arturo, Meregildo-Rodríguez, Edinson Dante, Miranda-Manrique, Gonzalo Francisco, Olivera-Chaupis, Marco, Ortega-Monasterios, Fatima Josefina, Otazú-Ybàñez, Jimmy Pedro, Paredes-Moreno, María Angélica, Peña-Mayorga, Claudia Ximena, Peña-Vàsquez, Olivia del Carmen, Peña-Villalobos, Alejandro, Ponce, Oscar J, Ponte-Fernandez, Katherin Estefania, Pro, Jose, Quispe-Nolazco, César Miguel, Ramos-Samanez, Manuel Efrain, Rojas-Murrugarra, Kory Mirtha, Samanez-Pérez, Jorge Mauro, Sànchez-Carrillo, Halbert Chrostian, Sànchez-Garavito, Epifanio, Sànchez-Sevillano, Ricardo Manuel, Sandoval-Manrique, Hernan, Santos-Revilla, Gabriela, Silva-Ramos, Julio Antonio, Solano-Ico, Manuel Alberto, Soto, Alonso, Sotomayor-Woolcott, Giannilu Michelle, Tapia-Orihuela, Ruben Kevin Arnold, Terrazas-Obregón, Carmen Sara, Terrones-Levano, Victor Francisco, Ticona-Huaroto, Cesar Eduardo, Torres-Ninapayta, Walter, Torres-Ruiz, Oscar Martin, Ugarte-Mercado, Dario, Vargas-Anahua, Orlando José, Vàsquez-Becerra, Ruben Dario, Vàsquez-Cerro, José Gabriel, Villegas-Chiroque, Miguel, Williams, Anna Larson, Yauri-Lazo, Randi Mauricio, Abad, Cybele Lara, Andales-Bacolcol, Silverose Ann, Arcegono, Marlon, Arches, Jamie, Astudillo, Mary Grace, Aventura, Emily, Awing, Arlyn, Bala, Mishelle Vonnabie, Bello, Jia An, Blanco, Peter, Benedicto, Jubert, Buno, Susana, Cabrera, Justine, Cajulao, Thea Pamela, Caoili, Janice, Casiple-Amsua, Lina, Catambing, Victor, Chin, Inofel, Chua, Ma. Bernadette, Chua, Mitzi Marie, Climacosa, Fresthel Monica, David-Wang, Aileen, De los Reyes, Virginia, Europa, Gilly May, Fernandez, Lenora, Francisco, Jorge, Garcia, Gerard, Garcia, Jemelyn, Gler, Maria Tarcela, Isidro, Marie Grace Dawn, Javier, Rozelle Jade, Kwek, Marion, Lansang, Mary Ann, Lee, Aileen, Li, Kingbherly, Llanes, Mark Ramon Victor, Llorin, Ryan, Macadato, Omar Khayyam, Malundo, Anna Flor, Mercado, Maria Elizabeth, Mujeres, Mercedes, Nepomuceno, Marisse, Ngo-Sanchez, Katha, Orden, Mary Claire, Pablo-Villamor, Maria Philina, Paez, Ruel Dionisio, Palmes, Patricio, Panaligan, Marion, Quinivista-Yoon, Jenny Mae, Ramos, Mary Shiela Ariola, Ramos -Penalosa, Christine, Reyes, Sheila Marie, Roa, Kathryn, Roman, Arthur Dessi, Rosario, Minette Claire, Roxas, Evalyn, Santos, Lourdes Ella Gonzales, Soldevilla, Helmar, Solante, Rontgene, Suaco, Jane, Tagarda, Daisy, Tang, Issa Rufina, Te, Bob, Teo, Dennis, Tibayan, Christopher John, Villalobos, Ralph Elvi, Ymbong, Duane Richard, Zabat, Gelza Mae, Batkova, Stepanka, Cardoso, Orlando, Garrote, Ana-Raquel, Lino, Sara, Manata, Maria-José, Pinheiro, Helder, Póvoas, Diana, Ramirez, Freddy, Seixas, Diana, Naji, Assem, Al Gethamy, M Al, AL-Mulaify, Mohammed Sami, Al Maghraby, Reem, Alrajhi, A, Al Sharidi, Aynaa, Alotaibi, Naif, AlShaharani, F, Barry, Mazin, Ghonem, Leen, Khalel, Anas, Kharaba, Ayman Mohammed, Alabdan, Lulwah, AlAbdullah, Mohammed Sharaf, Al Shabib, Abdullah, Bengu, Simangele, Bennet, Jacklyn, Dubula, Thozama, Howell, Pauline, Janse van Vuuren, Cloete, Kalla, Ismail, Lifson, Aimee, Maasdorp, Shaun, Magua, Nombulelo, Maluleke, Vongani, Mbhele, Nokuphiwa, Mdladla, Nathi, Mendelson, Mark, Menezes, Colin, Mwelase, Thando, Nchabeleng, Maphoshane, Palanee-Phillips, Thesla, Parker, Victoria, Rassool, Mohammed, Reeder, Paul, Sossen, Bianca, Steyn, Dewald, Tsitsi, Merika, van Blydenstein, Sarah Alex, Venter, Michelle, Van Vuuren, Janse, Venturas, Jacquie, Abad Pérez, Daniel, Abenza, Maria José, Alarcón-Payer, Carolina, Armero Garrigos, Eva, Arribas, Jose Ramon, Ascaso, Ana, Berenguer, Juan, Cabello-Clotet, Noemí, Chamorro Tojeiro, Sandra, Cuenca-Acevedo, Rafael, de la Calle, Fernando, Del Toro, Maria Dolores, Díaz Pollàn, Beatriz, Diez, Cristina, Esquillor-Rodrigo, María José, Estrada, Vicente, Fanciulli, Chiara, Fanjul, Francisco, Fernàndez de Orueta, Lucía, Ferre, Adrian, Ferreira Pasos, Eva Maria, Gainzarain-Arana, Juan-Carlos, Garcia, Felipe, García Deltoro, Miguel, Goikoetxea Agirre, Ane Josune, Gómez Barquero, Julia, Gomez-Huelgas, Ricardo, Gonzàlez Moraleja, Julio, Guijarro, Carlos, Gutierrez, Felix, Guzmàn, Jesús, Ibarguren, Maialen, Iribarren, Jose Antonio, Jerusalem, Koen, Juan Arribas, Arturo, Lalueza, A, Leone, Antonio, Lopez Azkarreta, Iñigo, Lozano-Martin, Daniel, Lucendo, Alfredo J, Luengo López, Mariella, Martín Oterino, JA, Masa, JF, Merino, Esperanza, Monge-Maillo, Begoña, Moran-Rodríguez, Miguel-Angel, Muñez Rubio, Elena, Muñoz Sanchez, Josefa, Nuñez Orantos, Maria Jose, Nuño, Enrique, Ortiz-De-Zarate-Ibarra, Zuriñe, Pagàn-Muñoz, Bàrbara, Paño-Pardo, José Ramón, Peñaranda, Maria, Pérez Chica, Gerardo, Pérez Fernàndez, AM, Pérez-López, Carmen, Polo San Ricardo, Victor, Portu-Zapirain, Joseba, Puchades, Francesco, Rivas Paterna, Ana Belen, Rodríguez Vidigal, Francisco F, Rodríguez-Baño, Jesus, Ruiz-Seco, Pilar, Ryan, Pablo, Saez-De-Adana, Ester, Salas, Rosario, Salavert Lletí, Miguel, Sandoval, Raquel, Toyas-Miazza, Carla, Valencia, Jorge, Vargas, Emilio, Velasco, Maria, Von Wichmann, Miguel Angel, Bosshard, Andreas, Calmy, Alexandra, Castro, Tiago, Cavassini, Matthias, Clerc, Olivier, Conen, Anna, Desbaillets, Nicolas, Desgranges, Florian, Duss, Francois, Emonet, Stephane, Erard, Veronique, Eyer, Myriam, Fayet-Mello, Aurélie, Flammer, Yvonne, Friedl, Andrée, Fulchini, Rosamaria, Furrer, Hansjakob, Garin, Nicolas, Gastberger, Salome, Greiner, Michael, Haefliger, David, Haubitz, Sebastian, Hoffmann, Matthias, Isenring, Egon, Jakopp, Barbara, Lampert, Markus, Marinosci, Annalisa, Martin, Yvonne, Petignat, Pierre-Auguste, Piso, Rein Jan, Prendki, Virginie, Rutishauser, Jonas, Schaefer, Elisabeth, Schmiedel, Yvonne, Schwery, Stefan, Stavropoulou, Elisavet, Stoeckle, Marcel, Suttels, Veronique, Thurnher, Maria Christine, van den Bogaart, Lorena, West, Emily, Wiegand, Jan, and Wiggli, Benedikt
- Published
- 2022
- Full Text
- View/download PDF
17. Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial
- Author
-
Blondon, Marc, Cereghetti, Sara, Pugin, Jérôme, Marti, Christophe, Darbellay Farhoumand, Pauline, Reny, Jean‐Luc, Calmy, Alexandra, Combescure, Christophe, Mazzolai, Lucia, Pantet, Olivier, Ltaief, Zied, Méan, Marie, Manzocchi Besson, Sara, Jeanneret, Séverin, Stricker, Hans, Robert‐Ebadi, Helia, Fontana, Pierre, Righini, Marc, and Casini, Alessandro
- Published
- 2022
- Full Text
- View/download PDF
18. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.
- Author
-
Begré, Lorin, Boyd, Anders, Plissonnier, Marie-Laure, Testoni, Barbara, Salazar-Vizcaya, Luisa, Suter-Riniker, Franziska, Scholtès, Caroline, Béguelin, Charles, Rockstroh, Jürgen K, Günthard, Huldrych F, Calmy, Alexandra, Cavassini, Matthias, Hirsch, Hans H, Schmid, Patrick, Bernasconi, Enos, Levrero, Massimo, Wandeler, Gilles, Zoulim, Fabien, Rauch, Andri, and Study, the Swiss HIV Cohort
- Subjects
HEPATITIS associated antigen ,HEPATITIS B virus ,SENSITIVITY & specificity (Statistics) ,MIXED infections ,TENOFOVIR - Abstract
Background We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study. Methods We included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates. Results HBsAg loss occurred after a median of 4 years (IQR, 1–8). All participants with HBsAg loss achieved suppressed HBV DNA and undetectable HBV RNA preceding undetectable quantitative HBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After 2 years of tenofovir therapy, an HBV RNA decline ≥1 log
10 copies/mL had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/mL had 91.0% sensitivity and 64.5% specificity. Conclusions HBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in persons with HIV. HBcrAg remained detectable in approximately 20% of persons with HBsAg loss and 50% of persons without HBsAg loss. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
19. Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort study
- Author
-
Blondet, Fanny, Kraege, Vanessa, Cavassini, Matthias, Damas Fernandez, José, Vollenweider, Peter, Wandeler, Gilles, Hoffman, Matthias, Calmy, Alexandra, Stoeckle, Marcel, Bernasconi, Enos, Hasse, Barbara, Marques-Vidal, Pedro, and Méan, Marie
- Published
- 2023
- Full Text
- View/download PDF
20. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
- Author
-
Labhardt, Niklaus D, Smit, Mikaela, Petignat, Ianis, Perneger, Thomas, Marinosci, Annalisa, Ustero, Pilar, Diniz Ribeiro, Maria Pia, Ragozzino, Silvio, Nicoletti, Giovanni Jacopo, Faré, Pietro Benedetto, Andrey, Diego O, Jacquerioz, Frederique, Lebowitz, Dan, Agoritsas, Thomas, Meyer, Benjamin, Spechbach, Hervé, Salamun, Julien, Guessous, Idris, Chappuis, François, Kaiser, Laurent, Decosterd, Laurent Arthur, Grinsztejn, Beatriz, Bernasconi, Enos, Cardoso, Sandra Wagner, Calmy, Alexandra, and Team, for the COPEP Study
- Published
- 2021
- Full Text
- View/download PDF
21. Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trial
- Author
-
Salamun, Julien, primary, Da Silva, Tamara, additional, Ustero, Pilar, additional, Gosmain, Yvan, additional, Guessous, Idris, additional, Calmy, Alexandra, additional, and Spechbach, Herve, additional
- Published
- 2024
- Full Text
- View/download PDF
22. Assessment of gender and geographical bias in the editorial decision-making process of biomedical journals: A Case-Control study
- Author
-
Gayet-Ageron, Angèle, primary, Messaoud, Khaoula Ben, additional, Richards, Mark, additional, Jaksic, Cyril, additional, Gobeill, Julien, additional, Liyanapathirana, Jeevanthi, additional, Mottin, Luc, additional, Naderi, Nona, additional, Ruch, Patrick, additional, Mariot, Zoé, additional, Calmy, Alexandra, additional, Friedman, Julia, additional, Leibovici, Leonard, additional, and Schroter, Sara, additional
- Published
- 2024
- Full Text
- View/download PDF
23. Patient and Public Involvement in HIV research: a mapping review and development of an online evidence map
- Author
-
Jackson-Perry, David, primary, Cart-Richter, Ellen, additional, Haerry, David, additional, Ahmeti, Lindrit, additional, Bieri, Annatina, additional, Calmy, Alexandra, additional, Ballif, Marie, additional, Pasin, Chloé, additional, Notter, Julia, additional, and Amstutz, Alain, additional
- Published
- 2024
- Full Text
- View/download PDF
24. Prophylaxis for COVID-19: a systematic review
- Author
-
Smit, Mikaela, Marinosci, Annalisa, Agoritsas, Thomas, and Calmy, Alexandra
- Published
- 2021
- Full Text
- View/download PDF
25. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV
- Author
-
Thoueille, Paul; https://orcid.org/0000-0002-2305-4277, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva; https://orcid.org/0000-0001-6776-4978, Veuve, François, Munting, Aline; https://orcid.org/0009-0006-2577-5912, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Braun, Dominique; https://orcid.org/0000-0003-4036-1030, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Duran Ramirez, Jessy J; https://orcid.org/0000-0001-6657-0688, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Furrer, Hansjakob; https://orcid.org/0000-0002-1375-3146, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Ustero, Pilar; https://orcid.org/0000-0001-8491-363X, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Stöckle, Marcel; https://orcid.org/0000-0002-0088-5078, Di Benedetto, Caroline, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Schmid, Patrick, Marzolini, Catia; https://orcid.org/0000-0002-2312-7050, Girardin, François R; https://orcid.org/0000-0002-0842-927X, Buclin, Thierry; https://orcid.org/0000-0003-0639-5536, Decosterd, Laurent A; https://orcid.org/0000-0002-9840-1325, Guidi, Monia; https://orcid.org/0000-0002-6419-9317, Thoueille, Paul; https://orcid.org/0000-0002-2305-4277, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva; https://orcid.org/0000-0001-6776-4978, Veuve, François, Munting, Aline; https://orcid.org/0009-0006-2577-5912, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Braun, Dominique; https://orcid.org/0000-0003-4036-1030, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Duran Ramirez, Jessy J; https://orcid.org/0000-0001-6657-0688, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Furrer, Hansjakob; https://orcid.org/0000-0002-1375-3146, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Ustero, Pilar; https://orcid.org/0000-0001-8491-363X, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Stöckle, Marcel; https://orcid.org/0000-0002-0088-5078, Di Benedetto, Caroline, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Schmid, Patrick, Marzolini, Catia; https://orcid.org/0000-0002-2312-7050, Girardin, François R; https://orcid.org/0000-0002-0842-927X, Buclin, Thierry; https://orcid.org/0000-0003-0639-5536, Decosterd, Laurent A; https://orcid.org/0000-0002-9840-1325, and Guidi, Monia; https://orcid.org/0000-0002-6419-9317
- Abstract
Long‐acting cabotegravir has been studied mainly in the stringent framework of clinical trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine clinical settings. The present population pharmacokinetic analysis aims to build real‐world reference percentile curves of cabotegravir concentrations, accounting for patient‐related factors that may affect cabotegravir exposure. The second objective is to simulate whether dosing interval adjustments of cabotegravir could be considered in specific subpopulations. Overall, 238 PWH contributed to 1,038 cabotegravir levels (186 during the initial oral administration phase and 852 after intramuscular injection). Cabotegravir pharmacokinetics was best described using a one‐compartment model with distinct first order‐absorption for oral and intramuscular administrations, and identical volume and clearance. Our model showed almost 40% faster absorption and 30% higher clearance than previously reported, resulting in a time to steady‐state of 8 months and an elimination half‐life of 4.6 weeks for long‐acting cabotegravir. Sex and body mass index significantly influenced absorption, and bodyweight affected clearance. Model‐based simulations showed that cabotegravir trough concentrations in females were 25% lower 4 weeks after the intramuscular loading dose, but 42% higher during the late maintenance phase. Finally, simulations indicated that in females, despite significantly higher cabotegravir concentrations, longer intervals between injections may not consistently ensure levels above the 4‐fold protein‐adjusted 90% inhibitory target concentration.
- Published
- 2024
26. Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL’HIV open-label, factorial randomised controlled trial
- Author
-
Marinosci, Annalisa; https://orcid.org/0000-0002-8054-0044, Sculier, Delphine; https://orcid.org/0000-0002-6741-9813, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Yerly, Sabine; https://orcid.org/0000-0003-1668-696X, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Vernazza, Pietro; https://orcid.org/0000-0002-6849-6941, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Buzzi, Marta, Metzner, Karin J; https://orcid.org/0000-0003-4862-1503, Decosterd, Laurent, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Schmid, Patrick, Limacher, Andreas; https://orcid.org/0000-0002-9094-9476, Branca, Mattia; https://orcid.org/0000-0002-8063-7882, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Marinosci, Annalisa; https://orcid.org/0000-0002-8054-0044, Sculier, Delphine; https://orcid.org/0000-0002-6741-9813, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Yerly, Sabine; https://orcid.org/0000-0003-1668-696X, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Vernazza, Pietro; https://orcid.org/0000-0002-6849-6941, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Buzzi, Marta, Metzner, Karin J; https://orcid.org/0000-0003-4862-1503, Decosterd, Laurent, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Schmid, Patrick, Limacher, Andreas; https://orcid.org/0000-0002-9094-9476, Branca, Mattia; https://orcid.org/0000-0002-8063-7882, and Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826
- Abstract
BACKGROUND: Clinical and laboratory monitoring of patients on antiretroviral therapy is an integral part of HIV care and determines whether treatment needs enhanced adherence or modification of the drug regimen. However, different monitoring and treatment strategies carry different costs and health consequences. MATERIALS AND METHODS: The SIMPL’HIV study was a randomised trial that assessed the non-inferiority of dual maintenance therapy. The co-primary outcome was a comparison of costs over 48 weeks of dual therapy with standard antiretroviral therapy and the costs associated with a simplified HIV care approach (patient-centred monitoring [PCM]) versus standard, tri-monthly routine monitoring. Costs included outpatient medical consultations (HIV/non-HIV consultations), non-medical consultations, antiretroviral therapy, laboratory tests and hospitalisation costs. PCM participants had restricted immunological and blood safety monitoring at weeks 0 and 48, and they were offered the choice to complete their remaining study visits via a telephone call, have medications delivered to a specified address, and to have blood tests performed at a location of their choice. We analysed the costs of both strategies using invoices for medical consultations issued by the hospital where the patient was followed, as well as those obtained from health insurance companies. Secondary outcomes included differences between monitoring arms for renal function, lipids and glucose values, and weight over 48 weeks. Patient satisfaction with treatment and monitoring was also assessed using visual analogue scales. RESULTS: Of 93 participants randomised to dolutegravir plus emtricitabine and 94 individuals to combination antiretroviral therapy (median nadir CD4 count, 246 cells/mm3; median age, 48 years; female, 17%),patient-centred monitoring generated no substantial reductions or increases in total costs (US$ –421 per year [95% CI –2292 to 1451]; p = 0.658). However, dual therapy was significa
- Published
- 2024
27. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocol
- Author
-
Hentzien, Maxime; https://orcid.org/0000-0003-2729-9420, Bonnet, Fabrice, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Biver, Emmanuel, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Munting, Aline; https://orcid.org/0009-0006-2577-5912, Leuzinger, Karoline; https://orcid.org/0000-0002-5654-9356, Leleux, Olivier, Musardo, Stefano, Prendki, Virginie, Schmid, Patrick, Staehelin, Cornelia, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Walti, Carla S, Wittkop, Linda, Appay, Victor, Didierlaurent, Arnaud M, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Hentzien, Maxime; https://orcid.org/0000-0003-2729-9420, Bonnet, Fabrice, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Biver, Emmanuel, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Munting, Aline; https://orcid.org/0009-0006-2577-5912, Leuzinger, Karoline; https://orcid.org/0000-0002-5654-9356, Leleux, Olivier, Musardo, Stefano, Prendki, Virginie, Schmid, Patrick, Staehelin, Cornelia, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Walti, Carla S, Wittkop, Linda, Appay, Victor, Didierlaurent, Arnaud M, and Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826
- Abstract
Background The burden of herpes zoster (shingles) virus and associated complications, such as post-herpetic neuralgia, is higher in older adults and has a significant impact on quality of life. The incidence of herpes zoster and post-herpetic neuralgia is increased in people living with HIV (PLWH) compared to an age-matched general population, including PLWH on long-term antiretroviral therapy (ART) with no detectable viremia and normal CD4 counts. PLWH – even on effective ART may- exhibit sustained immune dysfunction, as well as defects in cells involved in the response to vaccines. In the context of herpes zoster, it is therefore important to assess the immune response to varicella zoster virus vaccination in older PLWH and to determine whether it significantly differs to that of HIV-uninfected healthy adults or younger PLWH. We aim at bridging these knowledge gaps by conducting a multicentric, international, non-randomised clinical study (SHINGR’HIV) with prospective data collection after vaccination with an adjuvant recombinant zoster vaccine (RZV) in two distinct populations: in PLWH on long-term ART (> 10 years) over 50 years of and age/gender matched controls. Methods We will recruit participants from two large established HIV cohorts in Switzerland and in France in addition to age-/gender-matched HIV-uninfected controls. Participants will receive two doses of RZV two months apart. In depth-evaluation of the humoral, cellular, and innate immune responses and safety profile of the RZV will be performed to address the combined effect of aging and potential immune deficiencies due to chronic HIV infection. The primary study outcome will compare the geometric mean titer (GMT) of gE-specific total IgG measured 1 month after the second dose of RZV between different age groups of PLWH and between PLWH and age-/gender-matched HIV-uninfected controls. Discussion The SHINGR’HIV trial will provide robust data on the immunogenicity and safety profile of RZV in older PLWH
- Published
- 2024
28. Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study
- Author
-
Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Hauser, Anthony; https://orcid.org/0000-0002-7221-1929, Schwarzmüller, Magdalena; https://orcid.org/0000-0001-8384-2518, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Epp, Selina, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Battegay, Manuel; https://orcid.org/0000-0002-6638-3679, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Notter, Julia, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Fux, Christoph A, Leuzinger, Karoline; https://orcid.org/0000-0002-5654-9356, Perreau, Matthieu, Ramette, Alban; https://orcid.org/0000-0002-3437-4639, Gottschalk, Jochen, Schindler, Eméry, Wepf, Alexander, Marconato, Maddalena, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Frey, Beat M; https://orcid.org/0000-0002-2514-8621, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Huber, Michael; https://orcid.org/0000-0002-0384-0000, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Swiss HIV Cohort Study, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Hauser, Anthony; https://orcid.org/0000-0002-7221-1929, Schwarzmüller, Magdalena; https://orcid.org/0000-0001-8384-2518, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Epp, Selina, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Battegay, Manuel; https://orcid.org/0000-0002-6638-3679, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Notter, Julia, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Fux, Christoph A, Leuzinger, Karoline; https://orcid.org/0000-0002-5654-9356, Perreau, Matthieu, Ramette, Alban; https://orcid.org/0000-0002-3437-4639, Gottschalk, Jochen, Schindler, Eméry, Wepf, Alexander, Marconato, Maddalena, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Frey, Beat M; https://orcid.org/0000-0002-2514-8621, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Huber, Michael; https://orcid.org/0000-0002-0384-0000, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, and Swiss HIV Cohort Study
- Abstract
BACKGROUND Factors influencing susceptibility to SARS-CoV-2 remain to be resolved. Using data of the Swiss HIV Cohort Study (SHCS) on 6,270 people with HIV (PWH) and serologic assessment for SARS-CoV-2 and circulating-human-coronavirus (HCoV) antibodies, we investigated the association of HIV-related and general parameters with SARS-CoV-2 infection. METHODS We analyzed SARS-CoV-2 PCR-tests, COVID-19 related hospitalizations, and deaths reported to the SHCS between January 1, 2020 and December 31, 2021. Antibodies to SARS-CoV-2 and HCoVs were determined in pre-pandemic (2019) and pandemic (2020) bio-banked plasma and compared to HIV-negative individuals. We applied logistic regression, conditional logistic regression, and Bayesian multivariate regression to identify determinants of SARS-CoV-2 infection and Ab responses to SARS-CoV-2 in PWH. RESULTS No HIV-1-related factors were associated with SARS-CoV-2 acquisition. High pre-pandemic HCoV antibodies were associated with a lower risk of subsequent SARS-CoV-2 infection and with higher SARS-CoV-2 antibody responses upon infection. We observed a robust protective effect of smoking on SARS-CoV-2-infection risk (aOR= 0.46 [0.38,0.56], p=2.6*10-14), which occurred even in previous smokers, and was highest for heavy smokers. CONCLUSIONS Our findings of two independent protective factors, smoking and HCoV antibodies, both affecting the respiratory environment, underscore the importance of the local immune milieu in regulating susceptibility to SARS-CoV-2.
- Published
- 2024
29. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy
- Author
-
Begré, Lorin; https://orcid.org/0000-0003-1015-8947, Boyd, Anders; https://orcid.org/0000-0001-9512-8928, Plissonnier, Marie-Laure; https://orcid.org/0000-0003-4879-4586, Testoni, Barbara; https://orcid.org/0000-0001-5588-5465, Salazar-Vizcaya, Luisa; https://orcid.org/0000-0003-0527-0141, Suter-Riniker, Franziska; https://orcid.org/0000-0001-8568-578X, Scholtès, Caroline; https://orcid.org/0000-0003-0691-8480, Béguelin, Charles; https://orcid.org/0000-0001-9346-5146, Rockstroh, Jürgen K; https://orcid.org/0000-0003-2858-3888, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Hirsch, Hans H; https://orcid.org/0000-0003-0883-0423, Schmid, Patrick; https://orcid.org/0000-0003-1978-5082, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Levrero, Massimo; https://orcid.org/0000-0002-4978-0875, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Zoulim, Fabien; https://orcid.org/0000-0002-2245-0083, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Swiss HIV Cohort Study, Begré, Lorin; https://orcid.org/0000-0003-1015-8947, Boyd, Anders; https://orcid.org/0000-0001-9512-8928, Plissonnier, Marie-Laure; https://orcid.org/0000-0003-4879-4586, Testoni, Barbara; https://orcid.org/0000-0001-5588-5465, Salazar-Vizcaya, Luisa; https://orcid.org/0000-0003-0527-0141, Suter-Riniker, Franziska; https://orcid.org/0000-0001-8568-578X, Scholtès, Caroline; https://orcid.org/0000-0003-0691-8480, Béguelin, Charles; https://orcid.org/0000-0001-9346-5146, Rockstroh, Jürgen K; https://orcid.org/0000-0003-2858-3888, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Hirsch, Hans H; https://orcid.org/0000-0003-0883-0423, Schmid, Patrick; https://orcid.org/0000-0003-1978-5082, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Levrero, Massimo; https://orcid.org/0000-0002-4978-0875, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Zoulim, Fabien; https://orcid.org/0000-0002-2245-0083, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, and Swiss HIV Cohort Study
- Abstract
Background We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study. Methods We included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates. Results HBsAg loss occurred after a median of 4 years (IQR, 1–8). All participants with HBsAg loss achieved suppressed HBV DNA and undetectable HBV RNA preceding undetectable quantitative HBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After 2 years of tenofovir therapy, an HBV RNA decline ≥1 log10 copies/mL had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/mL had 91.0% sensitivity and 64.5% specificity. Conclusions HBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in persons with HIV. HBcrAg remained detectable in approximately 20% of persons with HBsAg loss and 50% of persons without HBsAg loss.
- Published
- 2024
30. Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy
- Author
-
Begré, Lorin; https://orcid.org/0000-0003-1015-8947, Boyd, Anders; https://orcid.org/0000-0001-9512-8928, Salazar-Vizcaya, Luisa; https://orcid.org/0000-0003-0527-0141, Suter-Riniker, Franziska, Béguelin, Charles; https://orcid.org/0000-0001-9346-5146, Rockstroh, Jürgen K, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Stöckle, Marcel; https://orcid.org/0000-0002-0088-5078, Schmid, Patrick, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Levrero, Massimo, Zoulim, Fabien, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Swiss HIV Cohort Study (SHCS), Begré, Lorin; https://orcid.org/0000-0003-1015-8947, Boyd, Anders; https://orcid.org/0000-0001-9512-8928, Salazar-Vizcaya, Luisa; https://orcid.org/0000-0003-0527-0141, Suter-Riniker, Franziska, Béguelin, Charles; https://orcid.org/0000-0001-9346-5146, Rockstroh, Jürgen K, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Stöckle, Marcel; https://orcid.org/0000-0002-0088-5078, Schmid, Patrick, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Levrero, Massimo, Zoulim, Fabien, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, and Swiss HIV Cohort Study (SHCS)
- Abstract
OBJECTIVES Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti-hepatitis B virus agents being developed. We evaluated long-term qHBsAg trajectories in persons with HIV and HBV during tenofovir-containing antiretroviral therapy in the Swiss HIV Cohort Study. METHODS We included 29 participants with and 29 without HBsAg loss, defined as qHBsAg <0.05 IU/mL. We assessed qHBsAg decline during therapy in both groups and used agglomerative hierarchical clustering to identify different qHBsAg trajectory profiles in persons with HBsAg loss. RESULTS The median follow-up time was 11.9 years (IQR 8.4-14.1), and the median time to HBsAg loss was 48 months (IQR 12-96). Among participants with HBsAg loss, 79% had a qHBsAg decline ≥1 log$_{10}$ IU/mL 2 years after starting tenofovir. The trajectories in qHBsAg levels during tenofovir therapy were heterogeneous, characterized by five distinct profiles. Among participants without HBsAg loss, only 7% had a qHBsAg decline ≥1 log$_{10}$ IU/ml after 2 years. CONCLUSIONS Most persons with HIV who experienced HBsAg loss had an early decline in qHBsAg levels, with diverse trajectories during long-term tenofovir therapy. In persons without HBsAg loss, qHBsAg levels remained remarkably stable over time.
- Published
- 2024
31. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
- Author
-
Thoueille, Paul, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva, Munting, Aline, Cavassini, Matthias, Braun, Dominique; https://orcid.org/0000-0003-4036-1030, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Surial, Bernard, Furrer, Hansjakob, Rauch, Andri, Rougemont, Mathieu, Ustero, Pilar, Calmy, Alexandra, Stöckle, Marcel, Marzolini, Catia, Di Benedetto, Caroline, Bernasconi, Enos, Schmid, Patrick, Piso, Rein Jan, Andre, Pascal, Girardin, François R, Guidi, Monia, Buclin, Thierry, Decosterd, Laurent A, Swiss HIV Cohort Study, Thoueille, Paul, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva, Munting, Aline, Cavassini, Matthias, Braun, Dominique; https://orcid.org/0000-0003-4036-1030, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Surial, Bernard, Furrer, Hansjakob, Rauch, Andri, Rougemont, Mathieu, Ustero, Pilar, Calmy, Alexandra, Stöckle, Marcel, Marzolini, Catia, Di Benedetto, Caroline, Bernasconi, Enos, Schmid, Patrick, Piso, Rein Jan, Andre, Pascal, Girardin, François R, Guidi, Monia, Buclin, Thierry, Decosterd, Laurent A, and Swiss HIV Cohort Study
- Abstract
BACKGROUND: The efficacy and tolerability of long-acting cabotegravir and rilpivirine were demonstrated in Phase III trials. However, low concentrations combined with other risk factors have been associated with an increased risk of virologic failure. This study aims to verify whether drug concentrations measured in a real-world setting are consistent with those previously reported. METHODS: SHCS-879 is a nationwide observational study within the Swiss HIV Cohort Study for the monitoring of people with HIV (PWH) on long-acting cabotegravir plus rilpivirine. Samples were collected from March 2022 to March 2023. FINDINGS: Overall, 725 samples were obtained from 186 PWH. Our data show a large inter-individual variability in cabotegravir and rilpivirine concentrations, with some individuals exhibiting repeatedly low concentrations. Rilpivirine trough concentrations were consistent with those from Phase III trials, while cabotegravir concentrations were lower. The first concentrations quartile was only slightly above the target of 664 ng/mL. Exploratory statistical analyses found 35% (p < 0·01) lower cabotegravir trough in males compared to females. Overall, 172 PWH (92%) remained suppressed and three experienced virologic failures (1·6%), of those, two had sub-optimal drug exposure. No association was found between low trough levels and detectable viral load. INTERPRETATION: Real-world cabotegravir concentrations are substantially lower than previously reported. However, these concentrations appear sufficient to ensure sustained virological suppression in almost every PWH. These reassuring data challenge the rather conservative thresholds adopted to date, which may raise unnecessary concerns. Yet, our study reveals that some PWH have repeatedly very low drug levels, for reasons that remain to be elucidated.
- Published
- 2024
32. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study
- Author
-
Baumann, Lukas; https://orcid.org/0000-0002-2778-2212, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Schmid, Patrick, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Haerry, David, Béguelin, Charles; https://orcid.org/0000-0001-9346-5146, Fux, Christoph A, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Baumann, Lukas; https://orcid.org/0000-0002-2778-2212, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Cavassini, Matthias; https://orcid.org/0000-0003-0933-7833, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Schmid, Patrick, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Haerry, David, Béguelin, Charles; https://orcid.org/0000-0001-9346-5146, Fux, Christoph A, Wandeler, Gilles; https://orcid.org/0000-0002-5278-8763, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, and Rauch, Andri; https://orcid.org/0000-0001-5297-6062
- Abstract
BACKGROUND AND AIMS: Treatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes in the prevalence of replicating HCV infection, treatment uptake and liver-related morbidity and mortality in persons with HIV (PWH) and hepatitis C in the Swiss HIV cohort study. METHODS: We included all cohort participants between 2002 and 2021. We assessed yearly prevalence of replicating HCV infection, overall and liver-related mortality, as well as the yearly incidence of liver-related events in persons with at least one documented positive HCV-RNA. RESULTS: Of 14 652 participants under follow-up, 2294 had at least one positive HCV-RNA measurement. Of those, 1316 (57%) ever received an HCV treatment. Treatment uptake increased from 8.1% in 2002 to a maximum of 32.6% in 2016. Overall, prevalence of replicating HCV infection declined from 16.5% in 2004 to 1.3% in 2021. HCV prevalence declined from 63.2% to 7.1% in persons who inject drugs, and from 4.1% to 0.6% in men who have sex with men. Among the 2294 persons with replicating HCV infection, overall mortality declined from a maximum of 3.3 per 100 patient-years (PY) to 1.1 per 100 PY, and incidence of liver-related events decreased from 1.4/100 PY to 0.2/100 PY. CONCLUSIONS: The introduction of DAA therapy was associated with a more than 10-fold reduction in prevalence of replicating HCV infection in PWH, approaching the estimates in the general population. Overall mortality and liver-related events declined substantially in persons living with HIV and hepatitis C.
- Published
- 2024
33. Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohort
- Author
-
Hovaguimian, Frédérique; https://orcid.org/0000-0003-4181-2948, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Schmidt, Axel J; https://orcid.org/0000-0002-6910-4399, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Notter, Julia, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Christinet, Vanessa, Darling, Katharine E A; https://orcid.org/0000-0003-1449-3873, Depmeier, Carsten, Läuchli, Severin, Reinacher, Matthias, Rasi, Manuela, Nicca, Dunja; https://orcid.org/0000-0002-4133-8177, Bruggmann, Philip, Haerry, David, Bize, Raphaël; https://orcid.org/0000-0001-5626-4628, Low, Nicola; https://orcid.org/0000-0003-4817-8986, Vock, Florian, El Amari, Emmanuelle Boffi, Böni, Jürg; https://orcid.org/0000-0001-7925-4852, Bosshard, Philipp P; https://orcid.org/0000-0002-1154-2281, Fehr, Jan S, Hampel, Benjamin, SwissPrEPared Cohort Study, Hovaguimian, Frédérique; https://orcid.org/0000-0003-4181-2948, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Schmidt, Axel J; https://orcid.org/0000-0002-6910-4399, Tarr, Philip E; https://orcid.org/0000-0002-1488-5407, Bernasconi, Enos; https://orcid.org/0000-0002-9724-8373, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Calmy, Alexandra; https://orcid.org/0000-0002-1137-6826, Notter, Julia, Stoeckle, Marcel; https://orcid.org/0000-0002-0088-5078, Surial, Bernard; https://orcid.org/0000-0002-1402-974X, Christinet, Vanessa, Darling, Katharine E A; https://orcid.org/0000-0003-1449-3873, Depmeier, Carsten, Läuchli, Severin, Reinacher, Matthias, Rasi, Manuela, Nicca, Dunja; https://orcid.org/0000-0002-4133-8177, Bruggmann, Philip, Haerry, David, Bize, Raphaël; https://orcid.org/0000-0001-5626-4628, Low, Nicola; https://orcid.org/0000-0003-4817-8986, Vock, Florian, El Amari, Emmanuelle Boffi, Böni, Jürg; https://orcid.org/0000-0001-7925-4852, Bosshard, Philipp P; https://orcid.org/0000-0002-1154-2281, Fehr, Jan S, Hampel, Benjamin, and SwissPrEPared Cohort Study
- Abstract
OBJECTIVES: Our objective was to obtain long-term data on the incidence of sexually transmitted infections (STIs) and their association with behavioural factors after widespread pre-exposure prophylaxis (PrEP) implementation. METHODS: This was a time-to-event analysis of a national PrEP cohort in Switzerland (SwissPrEPared study). Participants were people without HIV interested in taking PrEP with at least two STI screening visits. Primary outcomes were incidence rate of gonorrhoea, chlamydia, and syphilis. The association between behavioural factors and STI diagnosis was expressed using hazard ratios. We adjusted for testing frequency and calendar year. RESULTS: This analysis included 3907 participants enrolled between April 2019 and April 2022, yielding 3815.7 person-years of follow-up for gonorrhoea (15 134 screenings), 3802.5 for chlamydia (15 141 screenings), and 3858.6 for syphilis (15 001 screenings). The median age was 39 years (interquartile range [IQR] 32-47), 93.8% (n = 3664) identified as men who have sex with men (MSM). The incidence was 22.8 (95% confidence interval [CI] 21.3-24.4) per 100 person-years for gonorrhoea, 26.3 (95% CI 24.7-28.0) for chlamydia, and 4.4 (95% CI 3.8-5.1) for syphilis. Yearly incidence rates decreased between 2019 (all bacterial STIs: 81.6; 95% CI 59.1-109.9) and 2022 (all bacterial STIs: 49.8; 95% CI 44.6-55.3). Participants reporting chemsex substance use were at higher risk of incident STIs, as were those reporting multiple sexual partners. Younger age was associated with a higher risk of gonorrhoea and chlamydia. CONCLUSIONS: Incidence rates of bacterial STIs decreased over time. Young MSM, those with multiple partners, and those using chemsex substances were at increased risk of STIs.
- Published
- 2024
34. Clinical decision support systems to guide health care providers on HIV testing: a systematic review
- Author
-
Smit, Mikaela, Jordans, Carlijn C.E., Reinhard, Jitte M., Bramer, Wichor M., Verbon, Annelies, Rokx, Casper, and Calmy, Alexandra
- Published
- 2022
- Full Text
- View/download PDF
35. Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study.
- Author
-
Abela, Irene A, Hauser, Anthony, Schwarzmüller, Magdalena, Pasin, Chloé, Kusejko, Katharina, Epp, Selina, Cavassini, Matthias, Battegay, Manuel, Rauch, Andri, Calmy, Alexandra, Notter, Julia, Bernasconi, Enos, Fux, Christoph A, Leuzinger, Karoline, Perreau, Matthieu, Ramette, Alban, Gottschalk, Jochen, Schindler, Eméry, Wepf, Alexander, and Marconato, Maddalena
- Subjects
SARS-CoV-2 ,HIV ,CORONAVIRUSES ,POLYMERASE chain reaction ,ANTIBODY formation - Abstract
Background Factors influencing susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain to be resolved. Using data from the Swiss HIV Cohort Study on 6270 people with human immunodeficiency virus (HIV) and serologic assessment for SARS-CoV-2 and circulating human coronavirus (HCoV) antibodies, we investigated the association of HIV-related and general parameters with SARS-CoV-2 infection. Methods We analyzed SARS-CoV-2 polymerase chain reaction test results, COVID-19–related hospitalizations, and deaths reported to the Swiss HIV Cohort Study between 1 January 2020 and 31 December 2021. Antibodies to SARS-CoV-2 and HCoVs were determined in prepandemic (2019) and pandemic (2020) biobanked plasma samples and compared with findings in HIV-negative individuals. We applied logistic regression, conditional logistic regression, and bayesian multivariate regression to identify determinants of SARS-CoV-2 infection and antibody responses to SARS-CoV-2 in people with HIV. Results No HIV-1–related factors were associated with SARS-CoV-2 acquisition. High prepandemic HCoV antibodies were associated with a lower risk of subsequent SARS-CoV-2 infection and with higher SARS-CoV-2 antibody responses on infection. We observed a robust protective effect of smoking on SARS-CoV-2 infection risk (adjusted odds ratio, 0.46 [95% confidence interval,.38–.56]; P <.001), which occurred even in previous smokers and was highest for heavy smokers. Conclusions Our findings of 2 independent protective factors, smoking and HCoV antibodies, both affecting the respiratory environment, underscore the importance of the local immune milieu in regulating susceptibility to SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Similar Viral and Immune Characteristics of Kaposi Sarcoma in ART-treated People Living With HIV and Older Patients With Classic Kaposi Sarcoma.
- Author
-
Royston, Léna, Jary, Aude, Berini, Carolina A, Mabanga, Tsoarello, Lin, John, Pagliuzza, Amélie, Chomont, Nicolas, Litvinov, Ivan V, Calmy, Alexandra, Leducq, Valentin, Calvez, Vincent, Marcelin, Anne-Geneviève, Isnard, Stéphane, and Routy, Jean-Pierre
- Subjects
MONONUCLEAR leukocytes ,GRANULOCYTE-colony stimulating factor ,PLATELET-derived growth factor ,HIV ,KAPOSI'S sarcoma - Abstract
Background Reemergence of human herpesvirus 8 (HHV-8)–induced Kaposi sarcoma (KS) in people living with HIV (PLWH) despite antiretroviral therapy (ART) poses a clinical challenge because they already have favorable CD4 T-cell numbers and undetectable viral loads. We observed that clinical presentation in PLWH on ART resembled classic KS found in older HIV-uninfected patients and hypothesized that immunosenescence may thus play a role in occurrence of KS on ART. We compared viral and immune factors implicated in the development of KS in ART-treated PLWH (HIV KS) and HIV-uninfected classic KS patients (cKS), compared to controls without KS (HIV Control, cControls respectively). Methods Plasma, peripheral blood mononuclear cell, and skin tissues were obtained from 11 HIV KS and 11 cKS patients and 2 groups of age-matched controls. Results HIV KS participants were younger than cKS (aged 53 vs 75 years). HHV-8 genotypes did not differ between groups. Despite the younger age and a lower CD4/CD8 ratio, activated, exhausted, and senescent T-cell frequencies were similar between HIV KS and cKS. Anti–HHV-8 immunoglobulin G levels were higher and circulating HHV-8 DNA lower in HIV KS compared with cKS. Circulating platelet-derived growth factors AA-BB and granulocyte colony-stimulating factors were higher in HIV KS We observed similar levels of HHV-8 DNA and PD-1 expression in skin lesions from HIV KS and cKS patients. Conclusions Altogether, early immune senescence could be involved in the development of KS in ART-treated PLWH. Higher anti–HHV-8 immunoglobulin G levels could be linked with lower circulating viral load. Such insights should help developing therapeutical strategies to prevent development and treat KS in PLWH on ART. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV.
- Author
-
Thoueille, Paul, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva, Veuve, François, Munting, Aline, Cavassini, Matthias, Braun, Dominique, Günthard, Huldrych F., Duran Ramirez, Jessy J., Surial, Bernard, Furrer, Hansjakob, Rauch, Andri, Ustero, Pilar, Calmy, Alexandra, Stöckle, Marcel, Di Benedetto, Caroline, Bernasconi, Enos, Schmid, Patrick, and Marzolini, Catia
- Subjects
ORAL drug administration ,INTRAMUSCULAR injections ,HIV-positive persons ,PHARMACOKINETICS ,BODY mass index - Abstract
Long‐acting cabotegravir has been studied mainly in the stringent framework of clinical trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine clinical settings. The present population pharmacokinetic analysis aims to build real‐world reference percentile curves of cabotegravir concentrations, accounting for patient‐related factors that may affect cabotegravir exposure. The second objective is to simulate whether dosing interval adjustments of cabotegravir could be considered in specific subpopulations. Overall, 238 PWH contributed to 1,038 cabotegravir levels (186 during the initial oral administration phase and 852 after intramuscular injection). Cabotegravir pharmacokinetics was best described using a one‐compartment model with distinct first order‐absorption for oral and intramuscular administrations, and identical volume and clearance. Our model showed almost 40% faster absorption and 30% higher clearance than previously reported, resulting in a time to steady‐state of 8 months and an elimination half‐life of 4.6 weeks for long‐acting cabotegravir. Sex and body mass index significantly influenced absorption, and bodyweight affected clearance. Model‐based simulations showed that cabotegravir trough concentrations in females were 25% lower 4 weeks after the intramuscular loading dose, but 42% higher during the late maintenance phase. Finally, simulations indicated that in females, despite significantly higher cabotegravir concentrations, longer intervals between injections may not consistently ensure levels above the 4‐fold protein‐adjusted 90% inhibitory target concentration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
- Author
-
Kanters, Steve, Vitoria, Marco, Zoratti, Michael, Doherty, Meg, Penazzato, Martina, Rangaraj, Ajay, Ford, Nathan, Thorlund, Kristian, Anis, Prof. Aslam H., Karim, Mohammad Ehsanul, Mofenson, Lynne, Zash, Rebecca, Calmy, Alexandra, Kredo, Tamara, and Bansback, Nick
- Published
- 2020
- Full Text
- View/download PDF
39. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
- Author
-
Calmy, A, Tovar Sanchez, T, Kouanfack, C, Mpoudi-Etame, M, Leroy, S, Perrineau, S, Lantche-Wandji, M, Tetsa-Tata, D, Omgba-Bassega, P, Abong-Bwenda, T, Varloteaux, M, Tongo, M, Mpoudi-Ngolé, E, Montoyo, A, Mercier, N, LeMoing, V, Peeters, M, Reynes, J, Delaporte, E, Ayouba, A, Agholeng, A, Butel, C, Cournil, A, Eymard-Duvernay, S, Granouillac, B, Izard, S, Lacroix, A, Serrano, L, Vidal, N, Fouda, PJ, Mougnoutou, R, Olinga, J, Omgba, V, Tchokonte-Ngandé, SC, Ymele, B, Epoupa-Mpacko, CD, Fotso, M, Moukoko, R, Nké, T, Akamba, A, Lekelem, S, Tongo-Fotack, SB, Ngono, S, Tanga, M, Ebong, E, Edoul-Mbesse, G, Ciaffi, L, Koulla-Shiro, S, Manirakiza, G, Mimbé, ED, Boyer, S, Bousmah, M, Maradan, G, Nishimwe, ML, Spire, B, Lê, MP, Peytavin, G, Diallo, A, Fournier, I, Rekacewicz, C, Perez Casas, C, Calmy, Alexandra, Tovar Sanchez, Tamara, Kouanfack, Charles, Mpoudi-Etame, Mireille, Leroy, Sandrine, Perrineau, Ségolène, Lantche Wandji, Martial, Tetsa Tata, Darius, Omgba Bassega, Pierette, Abong Bwenda, Thérèse, Varloteaux, Marie, Tongo, Marcel, Mpoudi-Ngolé, Eitel, Montoyo, Alice, Mercier, Noémie, LeMoing, Vincent, Peeters, Martine, Reynes, Jacques, and Delaporte, Eric
- Published
- 2020
- Full Text
- View/download PDF
40. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
- Author
-
Phillips, Andrew N, Bansi-Matharu, Loveleen, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel R, Wensing, Annemarie, Lundgren, Jens D, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Ripin, David, Da Silva, Juliana, Raizes, Elliot, Ford, Nathan, Siberry, George K, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Calmy, Alexandra, and Bertagnolio, Silvia
- Published
- 2020
- Full Text
- View/download PDF
41. Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics
- Author
-
Kusejko, Katharina, Tschumi, Nadine, Chaudron, Sandra E., Nguyen, Huyen, Battegay, Manuel, Bernasconi, Enos, Böni, Jürg, Huber, Michael, Calmy, Alexandra, Cavassini, Matthias, Egle, Alexander, Grabmeier-Pfistershammer, Katharina, Haas, Bernhard, Hirsch, Hans, Klimkait, Thomas, Öllinger, Angela, Perreau, Matthieu, Ramette, Alban, Flury, Baharak Babouee, Sarcletti, Mario, Scherrer, Alexandra, Schmid, Patrick, Yerly, Sabine, Zangerle, Robert, Günthard, Huldrych F., and Kouyos, Roger D.
- Published
- 2022
- Full Text
- View/download PDF
42. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocol
- Author
-
Hentzien, Maxime, primary, Bonnet, Fabrice, additional, Bernasconi, Enos, additional, Biver, Emmanuel, additional, Braun, Dominique L, additional, Munting, Aline, additional, Leuzinger, Karoline, additional, Leleux, Olivier, additional, Musardo, Stefano, additional, Prendki, Virginie, additional, Schmid, Patrick, additional, Staehelin, Cornelia, additional, Stoeckle, Marcel, additional, Walti, Carla S, additional, Wittkop, Linda, additional, Appay, Victor, additional, Didierlaurent, Arnaud M, additional, and Calmy, Alexandra, additional
- Published
- 2024
- Full Text
- View/download PDF
43. Mpox: The alarm went off. Have we gone back to sleep?
- Author
-
Olliaro, Piero, primary, Bourner, Josephine, additional, Boum II, Yap, additional, Nakouné, Emmanuel, additional, Pesonel, Elise, additional, Rojek, Amanda, additional, Yazdanpanah, Yazdan, additional, Lescure, François-Xavier, additional, Calmy, Alexandra, additional, Grinsztejn, Beatriz, additional, Horby, Peter, additional, Merson, Laura, additional, and Dunning, Jake, additional
- Published
- 2024
- Full Text
- View/download PDF
44. Singularités du Covid-19 chez les personnes immunosupprimées
- Author
-
Chedid, Marie, primary, Hentzien, Maxime, additional, Eckerle, Isabella, additional, Fedeli, Chiara, additional, and Calmy, Alexandra, additional
- Published
- 2024
- Full Text
- View/download PDF
45. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
- Author
-
Thoueille, Paul, primary, Saldanha, Susana Alves, additional, Schaller, Fabian, additional, Choong, Eva, additional, Munting, Aline, additional, Cavassini, Matthias, additional, Braun, Dominique, additional, Günthard, Huldrych F., additional, Kusejko, Katharina, additional, Surial, Bernard, additional, Furrer, Hansjakob, additional, Rauch, Andri, additional, Rougemont, Mathieu, additional, Ustero, Pilar, additional, Calmy, Alexandra, additional, Stöckle, Marcel, additional, Marzolini, Catia, additional, Di Benedetto, Caroline, additional, Bernasconi, Enos, additional, Schmid, Patrick, additional, Piso, Rein Jan, additional, Andre, Pascal, additional, Girardin, François R., additional, Guidi, Monia, additional, Buclin, Thierry, additional, and Decosterd, Laurent A., additional
- Published
- 2024
- Full Text
- View/download PDF
46. Multicentric evaluation of a specific intrathecal anti-Treponema pallidumIgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case–control study
- Author
-
Alberto, Chloé, primary, Lambeng, Nathalie, additional, Deffert, Christine, additional, Breville, Gautier, additional, Gayet-Ageron, Angèle, additional, Lalive, Patrice, additional, Calmy, Alexandra, additional, Coste, Alix, additional, Papadimitriou-Olivgeris, Matthaios, additional, Braun, Dominique, additional, Lienhard, Reto, additional, Bosshard, Philipp Peter, additional, Fontao, Lionel, additional, and Toutous Trellu, Laurence, additional
- Published
- 2023
- Full Text
- View/download PDF
47. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment
- Author
-
Ford, Nathan, Vitoria, Marco, Rangaraj, Ajay, Norris, Susan L., Calmy, Alexandra, and Doherty, Meg
- Subjects
Efavirenz -- Usage ,Highly active antiretroviral therapy -- Usage -- Health aspects ,Coronaviruses -- Health aspects -- Usage ,Atazanavir -- Usage ,Emtricitabine -- Usage ,Drugs -- Usage ,Darunavir -- Usage -- Health aspects ,Medical research -- Health aspects -- Usage ,HIV -- Drug therapy -- Prevention -- Development and progression ,COVID-19 -- Development and progression -- Drug therapy -- Prevention ,Health ,World Health Organization - Abstract
Introduction: Several antiretroviral drugs are being considered for the treatment of COVID-19, the disease caused by a newly identified coronavirus, (SARS-CoV-2). We systematically reviewed the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials. Methods: Three databases were screened from inception to 30 March 2020 for studies reporting clinical outcomes of patients with SARS, MERS or COVID-19 treated with antiretrovirals. Results: From an initial screen of 433 titles, two randomized trials and 24 observational studies provided clinical outcome data on the use of antiretroviral drugs; most studies reported outcomes using LPV/r as treatment. Of the 21 observational studies reporting treatment outcomes, there were three studies among patients with SARS, six studies among patients with MERS and 12 studies among patients with COVID-19. In one randomized trial 99 patients with severe COVID-19 illness were randomized to receive LPV/r (400/100 mg twice a day) and 100 patients to standard of care for 14 days: LPV/r was not associated with a statistically significant difference in time to clinical improvement, although LPV/r given within 12 days of symptoms was associated with shorter time to clinical improvement; 28 day mortality was numerically lower in the LPV/r group (14/99) compared to the control group (25/100), but this difference was not statistically significant. The second trial found no benefit. The certainty of the evidence for the randomized trials was low. In the observational studies 3 out of 361 patients who received LPV/r died; the certainty of evidence was very low. Three studies reported a possible protective effect of LPV/r as post-exposure prophylaxis. Again, the certainty of the evidence was very low due to uncertainty due to limited sample size. Conclusions: On the basis of the available evidence it is uncertain whether LPV/r and other antiretrovirals improve clinical outcomes or prevent infection among patients at high risk of acquiring COVID-19. Keywords: antiretroviral therapy; HIV; MERS; SARS; coronavirus; COVID-19, 1 | INTRODUCTION Several antiretroviral drugs are being considered for use in the treatment of COVID-19, the disease caused by a newly identified coronavirus, (SARS-CoV-2). Protease inhibitors have been considered [...]
- Published
- 2020
- Full Text
- View/download PDF
48. Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort
- Author
-
Gencer, Baris, Pagano, Sabrina, Vuilleumier, Nicolas, Satta, Nathalie, Delhumeau-Cartier, Cécile, Meier, Christoph, Bavamian, Sabine, Montecucco, Fabrizio, Mach, François, and Calmy, Alexandra
- Published
- 2019
- Full Text
- View/download PDF
49. Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to action
- Author
-
Penazzato, Martina, Lockman, Shahin, Colbers, Angela, Renaud, Françoise, Calmy, Alexandra, Clayden, Polly, Vicari, Marissa, Mahaka, Imelda C., Zech, Jennifer M., Irvine, Cadi, and Abrams, Elaine J.
- Subjects
Antiviral agents -- Research ,Prenatal drug exposure -- Research ,Pharmaceutical research ,Pregnant women -- Drug therapy ,HIV infection -- Prevention -- Drug therapy ,Health - Abstract
: Introduction: Historical approaches to clinical development of novel therapeutics for treatment and prevention of HIV have led to unacceptable delays in the generation of data to support optimal antiretroviral drug use in pregnancy. Over the last 5 years, multiple stakeholders have voiced their concerns around the exclusion of pregnant women from drug trials, and some progress has been made to consolidate principles and forge consensus. Building on ongoing efforts, the World Health Organization (WHO) and the International Maternal Paediatric Adolescent AIDS Clinical Trials Network (IMPAACT) convened a technical consultation designed to move the discussion from theory to practice. Discussion: Accelerating the inclusion of pregnant women in pre‐licensure clinical trials, with a goal to have pharmacokinetics (PK) and preliminary safety data for all new HIV agents in pregnancy available at the time of drug approval, requires: (1) performing non‐clinical developmental and reproductive toxicology studies early in drug development for all new HIV agents; (2) recognizing and acting on the central role of women of childbearing potential affected by HIV through the research being conducted and the dissemination of associated results; (3) enrolling pregnant women in studies to specifically determine pregnancy PK and preliminary safety, as soon as late non‐clinical studies are completed with no negative signals, for all new HIV agents that have demonstrated preliminary evidence of safety and efficacy from phase 2 trials; (4) investigating adverse pregnancy and birth outcomes through dedicated pregnancy safety studies for all new priority HIV agents; and (5) expanding active surveillance of drug safety in pregnancy for rare events, such as birth defects. Strategic actions to pursue include developing tools and resources to support designing and implementing studies among pregnant and breastfeeding women, identifying and promoting modifications of the regulatory framework that are supportive of systematic ethical investigation of new drugs in pregnancy, coordinating surveillance efforts, mobilizing key stakeholders and promoting transparency and accountability for all involved. Conclusions: With more than 19 million women living with HIV worldwide, ensuring greater inclusion of pregnant women in research on novel therapeutics is a priority to support drug optimization and effective introduction of innovations for treatment and prevention of HIV., INTRODUCTION Despite tremendous work by the research community in exploring effective strategies to prevent HIV vertical transmission, historical approaches to clinical development of novel therapeutics for treatment and prevention of [...]
- Published
- 2022
- Full Text
- View/download PDF
50. Characterization and Determinants of Long-Term Immune Recovery Under Suppressive Antiretroviral Therapy.
- Author
-
Turk, Teja, Labarile, Marco, Braun, Dominique L., Rauch, Andri, Stöckle, Marcel, Cavassini, Matthias, Hoffmann, Matthias, Calmy, Alexandra, Bernasconi, Enos, Notter, Julia, Pasin, Chloé, Günthard, Huldrych F., and Kouyos, Roger D.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.